Skip to content

US · ATHE · BIOTECHNOLOGY

Alterity Therapeutics Limited (ATHE) intrinsic value and stock valuation

$1.52as of 2026-11-21 · Mkt cap 75.39M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alterity Therapeutics Limited DCF and intrinsic value

InvestorsCraft values ATHE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATHE’s statements →

Alterity Therapeutics Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Melbourne, VIC 3000 alteritytherapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$5.44M
20112025
Net income
-$-12.15M
20112025
Free cash flow
-$-11.45M
20112025
Total equity
$42.4M+32.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$5.44M$4.02M$3.92M$5.12M$4.34M
Operating income-$-14.57M-$-19.6M-$-14.64M-$-15.5M-$-15.18M
Net income-$-12.15M-$-19.12M-$-13.81M-$-12.85M-$-15.31M
EPSd-$-1.14M-$-3.14M-$-3.41M-$-3.2M-$-5.41M
Operating cash flow-$-11.45M-$-12.61M-$-20.04M-$-12.34M-$-17.33M
Capital expenditure$0.00-$-10K-$-10K-$-90K-$-10K
Free cash flow-$-11.45M-$-12.61M-$-20.04M-$-12.43M-$-17.34M
Total assets$46M$19.2M$27.3M$41.4M$33.6M
Total debt$160K$160K$210K$120K$70K
Net debt-$-33M-$-12.48M-$-15.56M-$-34.69M-$-28.05M
Total equity$42.4M$13.8M$22.8M$35.5M$30.5M
Cash and short-term investments$40.7M$12.6M$15.8M$34.8M$28.1M
Income statement
20252024202320222021
Revenue$5.44M$4.02M$3.92M$5.12M$4.34M
Cost of revenue$130K$210K$290K$360K$360K
Gross profit$5.31M$3.8M$3.63M$4.76M$3.98M
Research and development expenses$14.4M$18.6M$13.2M$14.8M$12.3M
Selling, general and administrative expenses$5.48M$4.76M$5.04M$5.51M$6.87M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$19.9M$23.4M$18.2M$20.3M$19.2M
Cost and expenses$20M$23.6M$18.5M$20.6M$19.5M
Interest income$450K$270K$20K$0.00$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$30K$40K$40K$50K$20K
Ebitda-$-14.63M-$-19.57M-$-14.6M-$-17.39M-$-15.16M
Operating income-$-14.57M-$-19.6M-$-14.64M-$-15.5M-$-15.18M
Total other income/expenses, net$2.49M$520K$900K$2.72M-$-130K
Income before tax-$-12.08M-$-19.08M-$-13.7M-$-12.78M-$-15.31M
Income tax expense$70K$50K$100K$70K-$-3.08M
Net income-$-12.15M-$-19.12M-$-13.81M-$-12.85M-$-15.31M
Weighted average shares outstanding$10.7M$6.08M$4.05M$4.01M$2.83M
Weighted average diluted shares outstanding$10.7M$6.08M$4.05M$4.01M$2.83M
Balance sheet
20252024202320222021
Cash and short-term investments$40.7M$12.6M$15.8M$34.8M$28.1M
Net receivables$3.94M$4.04M$8.65M$4.67M$4.13M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$45.9M$19M$27.1M$41.1M$33.5M
Property, plant and equipment, net$160K$190K$270K$220K$100K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$160K$190K$270K$220K$100K
Total assets$46M$19.2M$27.3M$41.4M$33.6M
Accounts payable$540K$580K$1.72M$2.64M$1.45M
Short-term debt$70K$110K$110K$60K$30K
Deferred revenue$0.00$0.00-$-110K-$-60K$0.00
Total current liabilities$3.53M$5.37M$4.38M$5.82M$3.07M
Long-term debt$90K$50K$100K$60K$40K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90K$50K$120K$70K$50K
Capital lease obligations$160K$160K$210K$120K$70K
Total liabilities$3.62M$5.43M$4.5M$5.89M$3.12M
Common stock$263M$223.2M$214M$213.8M$197.5M
Retained earnings-$-225.89M-$-214.16M-$-195.13M-$-181.88M-$-169.73M
Accumulated other comprehensive income (loss)$5.34M$4.81M$3.97M$3.57M$2.75M
Total equity$42.4M$13.8M$22.8M$35.5M$30.5M
Total investments$7.5M$0.00$0.00$0.00$0.00
Total debt$160K$160K$210K$120K$70K
Net debt-$-33M-$-12.48M-$-15.56M-$-34.69M-$-28.05M
Cash flow statement
20252024202320222021
Net income-$-12.15M-$-19.12M-$-13.81M-$-12.85M-$-15.31M
Depreciation and amortization$140K$150K$100K$50K$80K
Stock-based compensation$980K$880K$970K$1.51M$1.88M
Change in working capital-$-610K$5.75M-$-3.94M-$-450K-$-4.22M
Accounts receivable$100K$4.62M-$-3.94M-$-450K-$-4.22M
Inventory$0.00$0.00$2.45M-$-2.21M$190K
Accounts payable$0.00$1.1M-$-1.56M$2.6M$430K
Net cash provided by operating activities-$-11.45M-$-12.61M-$-20.04M-$-12.34M-$-17.33M
Investments in property, plant and equipment$0.00-$-10K-$-10K-$-90K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-7.5M-$-10K-$-40K-$-90K-$-10K
Common stock issued$42.6M$10.1M$320K$17.2M$39.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$39.7M$9.22M$120K$16.3M$36.7M
Net change in cash$20.5M-$-3.13M-$-19.03M$6.69M$18.9M
Cash at end of period$33.2M$12.6M$15.8M$34.8M$28.1M
Operating cash flow-$-11.45M-$-12.61M-$-20.04M-$-12.34M-$-17.33M
Capital expenditure$0.00-$-10K-$-10K-$-90K-$-10K
Free cash flow-$-11.45M-$-12.61M-$-20.04M-$-12.43M-$-17.34M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alterity Therapeutics Limited

        Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

        CEO
        David A. Stamler
        Employees
        9
        Beta
        -0.03

        Explore

        Frequently asked questions

        What is the intrinsic value of Alterity Therapeutics Limited (ATHE)?

        Alterity Therapeutics Limited (ATHE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATHE undervalued?

        ATHE trades at a price of $1.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.